Animal studies showed potential risks to developing babies
Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsuits and Super Bowl ads tell us about where obesity treatment is headed next
This came into force in 1988
The success of these therapies has paved the way for the development of next-generation treatments, including multi-agonist molecules like Tirzepatide (Mounjaro/Zepbound) or Retatrutide (LY3437943) that simultaneously target several metabolic receptors to achieve improved metabolic outcomes in obese or diabetic patients [3,6]
Once your thyroid function is stable, we can evaluate whether GLP-1 therapy is an appropriate and powerful next step in your journey toward metabolic health, sustainable weight loss, and improved quality of life
Concerns about compounded semaglutide: This medicine may increase the risk of having thyroid tumors